A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

Summary

The main purpose of this study is to assess how well the study drug (JNJ-42847922) works (efficacy) compared with placebo in improving depressive symptoms in participants with major depressive disorder ([MDD], a common mood disorder that causes a lasting feeling of sadness and a loss of interest in everyday activities) in double-blind treatment phase. Further, to evaluate long-term safety and tolerability of JNJ-42847922 in participants with MDD in the open label treatment phase.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Depressive Disorder, Major

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

18 to 74 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Janssen Research & Development, LLC

Last updated on ClinicalTrials.gov

October 1, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites